Business Description
Kura Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US50127T1097
Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 31.06 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -7 | |||||
| 3-Year EPS without NRI Growth Rate | -7.2 | |||||
| 3-Year FCF Growth Rate | -7.9 | |||||
| 3-Year Book Growth Rate | -16.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.45 | |||||
| 9-Day RSI | 46.41 | |||||
| 14-Day RSI | 47.63 | |||||
| 6-1 Month Momentum % | 47.85 | |||||
| 12-1 Month Momentum % | 101.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.67 | |||||
| Quick Ratio | 16.67 | |||||
| Cash Ratio | 16.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -15.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -38.43 | |||||
| ROA % | -35.06 | |||||
| ROIC % | -802.72 | |||||
| ROC (Joel Greenblatt) % | -2217.45 | |||||
| ROCE % | -36.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.2 | |||||
| Price-to-Tangible-Book | 3.2 | |||||
| EV-to-EBIT | -6.64 | |||||
| EV-to-Forward-EBIT | -4.95 | |||||
| EV-to-EBITDA | -6.67 | |||||
| EV-to-Forward-EBITDA | -4.95 | |||||
| EV-to-Forward-Revenue | 10.12 | |||||
| EV-to-FCF | -8.01 | |||||
| Price-to-Net-Current-Asset-Value | 3.3 | |||||
| Price-to-Net-Cash | 3.38 | |||||
| Earnings Yield (Greenblatt) % | -15.06 | |||||
| FCF Yield % | -8.55 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers